In conclusion, the results reported in this manuscript indicate that PI3KCA over-expression occur at a much higher frequency in lung cancers than do activating mutations, apparently representing the major determinant of AKT activation in NSCLC. The gene discussed is AKT1; the disease is lung cancer.